In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...
On May 29, Goldman Sachs analyst David Roman initiated coverage DexCom Inc. (NASDAQ:DXCM) with a Buy rating and a price target of $104. The initiation is part of Goldman Sachs’s broader coverage ...
DexCom, a developer of continuous glucose monitoring systems, has collaborated with Google-turned-Alphabet’s Life Sciences division to develop new products that will be smaller and less expensive than ...
Oct 30 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback